25 XP 0   0   10  
0coffee
Main menu
3rd party ad coffee SUPPORTERis ad-free.

Endonovo Therapeutics Inc
Buy, Hold or Sell?

Let's analyze Endonovo together

I guess you are interested in Endonovo Therapeutics Inc. Buy, hold or sell? I don't know! However, I do recommend doing research before doing anything. I will help you with that.

I'm going to help you getting a better view of Endonovo Therapeutics Inc. At the end you don't have to ask anyone for trading advice. You can make your own decision, with more confidence, the odds in your favor, backed by data.

Get notifications about Endonovo Therapeutics Inc

I send you an email if I find something interesting about Endonovo Therapeutics Inc.

Quick analysis of Endonovo (30 sec.)










What can you expect buying and holding a share of Endonovo? (30 sec.)

How much money do you get?

How much money do you get?
$0.00
When do you have the money?
1 year
How often do you get paid?
0.0%

What is your share worth?

Current worth
$-0.04
Expected worth in 1 year
$0.01
How sure are you?
22.5%

+ What do you gain per year?

Total Gains per Share
$0.05
Return On Investment
4,370.7%

For what price can you sell your share?

Current Price per Share
$0.00
Expected price per share
$0.0008 - $0.0018
How sure are you?
50%
3rd party ad coffee SUPPORTERis ad-free.

1. Valuation of Endonovo (5 min.)




Live pricePrice per Share (EOD)

$0.00

Intrinsic Value Per Share

$-0.03 - $0.02

Total Value Per Share

$-0.07 - $-0.02

2. Growth of Endonovo (5 min.)




Is Endonovo growing?

Current yearPrevious yearGrowGrow %
How rich?-$24.8m-$25.7m$2.2m9.6%

How much money is Endonovo making?

Current yearPrevious yearGrowGrow %
Making money-$253.8k-$6.7m$6.5m2,565.9%
Net Profit Margin-20,276.8%-131,509.6%--

How much money comes from the company's main activities?

3. Financial Health of Endonovo (5 min.)




4. Comparing to competitors in the Biotechnology industry (5 min.)




  Industry Rankings (Biotechnology)  


Richest
#939 / 982

Most Revenue
#760 / 982

Most Profit
#176 / 982

Most Efficient
#933 / 982
3rd party ad coffee SUPPORTERis ad-free.

What can you expect buying and holding a share of Endonovo? (5 min.)

Welcome investor! Endonovo's management wants to use your money to grow the business. In return you get a share of Endonovo.

What can you expect buying and holding a share of Endonovo?

First you should know what it really means to hold a share of Endonovo. And how you can make/lose money.

Speculation

The Price per Share of Endonovo is $0.0012. The market price reflects what other people think it is worth; not what it's really worth. Your job is to find out if the market price is fair, overpriced, or underpriced. I will help you with that.

If you buy blind, there is a 50% chance of making or losing money by selling the stock in the future. However, we can look at a few things to determine the odds in our favor:

  • The fundamentals: the financial health trends of Endonovo.
  • The technials: based on market psychology, we can make a calculated estimate of what the price will do in the future. We can do this through technical analysis. We can calculate the probabilities and the expected value (millionaire math). That's called speculation.
  • The book value: what is the market price compared to it's book value.

Investing

If you really want to invest in Endonovo, you will have to let go of the thought of selling in the future. If you have to sell the share for less than you bought it, it can still be a good investment. Focus on what it means to hold the stock forever:

  • You own a part of the company. The equity of this part can grow or shrink. The current Book Value per Share is $-0.04. Based on the TTM, the Book Value Change Per Share is $0.01 per quarter. Based on the YOY, the Book Value Change Per Share is $-0.01 per quarter.
  • You may receive quarterly/yearly dividend in the form of additional shares.
  • You may receive quarterly/yearly dividend in the form of cash. Based on the TTM the Dividend per Share is $0.00 per quarter.
Based on historical numbers we can estimate the returns while holding a share of Endonovo.

How much money are you going to get?

 MRQTTMYOY5Y10Y
 $% of Price per Share$% of Price per Share$% of Price per Share$% of Price per Share$% of Price per Share
Usd Eps0.00-94.5%0.00-133.1%-0.02-1,564.2%-0.01-587.8%-0.01-485.5%
Usd Book Value Change Per Share0.032,445.0%0.011,092.7%-0.01-978.2%0.00-29.4%0.00-58.0%
Usd Dividend Per Share0.000.0%0.000.0%0.000.0%0.000.0%0.000.0%
Usd Total Gains Per Share0.032,445.0%0.011,092.7%-0.01-978.2%0.00-29.4%0.00-58.0%
Usd Price Per Share0.00-0.01-0.01-0.13-0.33-
Price to Earnings Ratio-0.68--0.06--0.41--2.44--34.06-
Price-to-Total Gains Ratio0.11--0.65--2.41--16.16--771.94-
Price to Book Ratio-0.08--0.32--0.17--2.32--19.05-
Price-to-Total Gains Ratio0.11--0.65--2.41--16.16--771.94-

When do you get the money?

Usd Investment
$.00
Usd Price Per Share0.0012
Number of shares833333
Gains per QuarterTrailing 12 Months5 Year
Usd Dividend Per Share0.000.00
Usd Book Value Change Per Share0.010.00
Usd Total Gains Per Share0.010.00
Gains per Quarter (833333 shares)10,926.70-293.77
Gains per Year (833333 shares)43,706.82-1,175.08
YearsReturn on Investment (TTM)Return on Investment (5Y)
 DividendBook Value gainTotal gainsDividendBook Value gainTotal gains
Broker costs---10---10
1043707436970-1175-1185
2087414874040-2350-2360
301311201311110-3525-3535
401748271748180-4700-4710
502185342185250-5875-5885
602622412622320-7050-7060
703059483059390-8226-8235
803496553496460-9401-9410
903933613933530-10576-10585
1004370684370600-11751-11760

How sure are you?

Based on the past periods, how sure are you to get value out of your investment.

Linear %
 Trailing 12 Months3Y5 Year10 YearALLTIME
  % % % % %
Earnings Per Share1.03.00.025.0%2.010.00.016.7%3.017.00.015.0%7.033.00.017.5%7.045.00.013.5%
Book Value Change Per Share2.02.00.050.0%3.07.02.025.0%4.012.04.020.0%9.024.07.022.5%10.032.010.019.2%
Dividend per Share0.00.04.00.0%0.00.012.00.0%0.00.020.00.0%0.00.040.00.0%0.00.052.00.0%
Total Gains per Share2.02.00.050.0%3.07.02.025.0%4.012.04.020.0%9.024.07.022.5%10.032.010.019.2%
3rd party ad coffee SUPPORTERis ad-free.

Fundamentals of Endonovo

About Endonovo Therapeutics Inc

Endonovo Therapeutics, Inc., a biotechnology company, develops, manufactures, and distributes non-invasive Electroceutical medical devices for regenerative medicine. The company offers SofPulse, a non-invasive Electroceutical therapeutic device for the palliative treatment of soft tissue injuries, chronic wounds, and post-operative pain and edema. Its Electroceuticals medical device is also used for the treatment of cardiovascular diseases, chronic kidney, liver diseases, non-alcoholic steatohepatitis, cardiovascular and peripheral artery diseases, and ischemic stroke, as well as for central nervous system disorders, such as traumatic brain injury, acute concussions, post-concussion syndrome, stroke, and multiple sclerosis. Endonovo Therapeutics, Inc. was founded in 2008 and is based in Woodland Hills, California.

Fundamental data was last updated by Penke on 2024-07-19 11:45:02.

Financial Health

Profitability Details
 Compared to previous yearCompared to industry
The company is making a huge loss.
Using its assets, the company is very inefficient in making profit.
Operating Efficiency Details
 Compared to previous yearCompared to industry
The company is operating very inefficient.
The company is inefficient in keeping operating costs low.
Liquidity Details
 Compared to previous yearCompared to industry
The company is unable to pay all its short-term debts.
The company is just not able to pay all its short-term debts with the most liquid assets.
Solvency Details
 Compared to previous yearCompared to industry
The company is unable to pay all its debts by selling its assets.

Valuation

Valuation Details
 Compared to previous yearCompared to industry
Based on the equity, the company is expensive.
Based on the earnings, the company is expensive.
Based on how much money comes from the company's main activities, the company is expensive.
3rd party ad coffee SUPPORTERis ad-free.

1.1. Profitability of Endonovo Therapeutics Inc.

1.1. Profitability
1.1.1. Net Profit Margin

Measures how much net profit Endonovo earns for each $1 of revenue.

  • Above 10% is considered healthy but always compare Endonovo to the Biotechnology industry mean.
  • A Net Profit Margin of -8,463.1% means that $-84.63 for each $1 in revenue is generated as profit.

Let's take a look of the Net Profit Margin trends of Endonovo Therapeutics Inc:

  • The MRQ is -8,463.1%. The company is making a huge loss. -2
  • The TTM is -20,276.8%. The company is making a huge loss. -2
Trends
Current periodCompared to+/- 
MRQ-8,463.1%TTM-20,276.8%+11,813.7%
TTM-20,276.8%YOY-131,509.6%+111,232.9%
TTM-20,276.8%5Y41,065.2%-61,341.9%
5Y41,065.2%10Y28,722.6%+12,342.6%
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ-8,463.1%-168.6%-8,294.5%
TTM-20,276.8%-209.9%-20,066.9%
YOY-131,509.6%-235.1%-131,274.5%
5Y41,065.2%-390.8%+41,456.0%
10Y28,722.6%-505.1%+29,227.7%
1.1.2. Return on Assets

Shows how efficient Endonovo is using its assets to generate profit.

  • Above 5% is considered healthy but always compare Endonovo to the Biotechnology industry mean.
  • -148.9% Return on Assets means that Endonovo generated $-1.49 profit for each $1 in assets.

Let's take a look of the Return on Assets trends of Endonovo Therapeutics Inc:

  • The MRQ is -148.9%. Using its assets, the company is very inefficient in making profit. -2
  • The TTM is -72.5%. Using its assets, the company is very inefficient in making profit. -2
Trends
Current periodCompared to+/- 
MRQ-148.9%TTM-72.5%-76.4%
TTM-72.5%YOY-514.0%+441.5%
TTM-72.5%5Y-153.2%+80.7%
5Y-153.2%10Y-515.5%+362.3%
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ-148.9%-11.7%-137.2%
TTM-72.5%-11.8%-60.7%
YOY-514.0%-11.2%-502.8%
5Y-153.2%-13.2%-140.0%
10Y-515.5%-14.6%-500.9%
1.1.3. Return on Equity

Shows how efficient Endonovo is using its investors money to generate profit.

  • Above 15%-20% is considered healthy but always compare Endonovo to the Biotechnology industry mean.
  • 0.0% Return on Equity means Endonovo generated $0.00 for each $1 the owners (shareholders) invested.

Let's take a look of the Return on Equity trends of Endonovo Therapeutics Inc:

  • The MRQ is 0.0%. The data is not here.
Trends
Current periodCompared to+/- 
MRQ-TTM-0.0%
TTM-YOY-0.0%
TTM-5Y-0.0%
5Y-10Y-0.0%
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ--14.0%+14.0%
TTM--15.2%+15.2%
YOY--14.0%+14.0%
5Y--18.8%+18.8%
10Y--19.3%+19.3%
3rd party ad coffee SUPPORTERis ad-free.

1.2. Operating Efficiency of Endonovo Therapeutics Inc.

1.2. Operating Efficiency
1.2.1. Operating Margin

Measures how efficient Endonovo is operating .

  • Measures how much profit Endonovo makes for each $1 of sales after paying variable costs (production costs, wages, etc) but before taxes.
  • Above 15% is considered healthy but always compare Endonovo to the Biotechnology industry mean.
  • An Operating Margin of -4,772.6% means the company generated $-47.73  for each $1 in revenue (before taxes).

Let's take a look of the Operating Margin trends of Endonovo Therapeutics Inc:

  • The MRQ is -4,772.6%. The company is operating very inefficient. -2
  • The TTM is -13,011.7%. The company is operating very inefficient. -2
Trends
Current periodCompared to+/- 
MRQ-4,772.6%TTM-13,011.7%+8,239.1%
TTM-13,011.7%YOY-70,514.7%+57,503.0%
TTM-13,011.7%5Y-30,311.5%+17,299.7%
5Y-30,311.5%10Y-13,579.1%-16,732.4%
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ-4,772.6%-351.1%-4,421.5%
TTM-13,011.7%-224.3%-12,787.4%
YOY-70,514.7%-243.1%-70,271.6%
5Y-30,311.5%-396.3%-29,915.2%
10Y-13,579.1%-510.1%-13,069.0%
1.2.2. Operating Ratio

Measures how efficient Endonovo is keeping operating costs low.

  • Below 1 is considered healthy (always compare to Biotechnology industry mean).
  • An Operation Ratio of 48.73 means that the operating costs are $48.73 for each $1 in net sales.

Let's take a look of the Operating Ratio trends of Endonovo Therapeutics Inc:

  • The MRQ is 48.725. The company is inefficient in keeping operating costs low. -1
  • The TTM is 130.696. The company is inefficient in keeping operating costs low. -1
Trends
Current periodCompared to+/- 
MRQ48.725TTM130.696-81.971
TTM130.696YOY706.157-575.460
TTM130.6965Y303.536-172.840
5Y303.53610Y98.779+204.757
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ48.7253.004+45.721
TTM130.6963.255+127.441
YOY706.1573.484+702.673
5Y303.5365.004+298.532
10Y98.7796.533+92.246
3rd party ad coffee SUPPORTERis ad-free.

1.3. Liquidity of Endonovo Therapeutics Inc.

1.3. Liquidity
1.3.1. Current Ratio

Measures if Endonovo is able to pay off Short-term Debt.

  • Above 1.5 is considered healthy (always compare to Biotechnology industry mean).
  • A Current Ratio of 0.00 means the company has $0.00 in assets for each $1 in short-term debts.

Let's take a look of the Current Ratio trends of Endonovo Therapeutics Inc:

  • The MRQ is 0.001. The company is unable to pay all its short-term debts. -2
  • The TTM is 0.002. The company is unable to pay all its short-term debts. -2
Trends
Current periodCompared to+/- 
MRQ0.001TTM0.002-0.001
TTM0.002YOY0.001+0.001
TTM0.0025Y0.003-0.002
5Y0.00310Y0.010-0.006
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ0.0013.793-3.792
TTM0.0024.052-4.050
YOY0.0014.945-4.944
5Y0.0035.990-5.987
10Y0.0106.326-6.316
1.3.2. Quick Ratio

Measures if Endonovo is able to pay off Short-term Debt but only using the most liquid assets.

  • Above 1 is considered healthy but always compare Endonovo to the Biotechnology industry mean.
  • A Quick Ratio of 0.00 means the company can pay off $0.00 for each $1 in debt (using most liquid assets).

Let's take a look of the Quick Ratio trends of Endonovo Therapeutics Inc:

  • The MRQ is 0.000. The company is just not able to pay all its short-term debts with the most liquid assets. -1
  • The TTM is 0.000. The company is just not able to pay all its short-term debts with the most liquid assets. -1
Trends
Current periodCompared to+/- 
MRQ0.000TTM0.0000.000
TTM0.000YOY0.000+0.000
TTM0.0005Y0.002-0.002
5Y0.00210Y0.005-0.003
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ0.0003.186-3.186
TTM0.0003.581-3.581
YOY0.0004.803-4.803
5Y0.0025.922-5.920
10Y0.0056.430-6.425
3rd party ad coffee SUPPORTERis ad-free.

1.4. Solvency of Endonovo Therapeutics Inc.

1.3. Liquidity
1.4.1. Debt to Asset Ratio

Measures how much % of Endonovo assets are financed with debt.

  • Below 1 (100%) is considered healthy but always compare Endonovo to Biotechnology industry mean.
  • A Debt to Asset Ratio of 53.07 means that Endonovo assets are financed with 5,307.0% credit (debt) and the remaining percentage (100% - 5,307.0%) is financed by its owners/shareholders. 

Let's take a look of the Debt to Asset Ratio trends of Endonovo Therapeutics Inc:

  • The MRQ is 53.070. The company is unable to pay all its debts by selling its assets. -2
  • The TTM is 35.945. The company is unable to pay all its debts by selling its assets. -2
Trends
Current periodCompared to+/- 
MRQ53.070TTM35.945+17.125
TTM35.945YOY19.939+16.006
TTM35.9455Y15.423+20.521
5Y15.42310Y32.489-17.065
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ53.0700.330+52.740
TTM35.9450.340+35.605
YOY19.9390.287+19.652
5Y15.4230.368+15.055
10Y32.4890.383+32.106
1.4.2. Debt to Equity Ratio

Measures if Endonovo is able to pay off its debts by using shareholders equity.

  • Below 2 is considered healthy but always compare Endonovo to the Biotechnology industry mean.
  • A Debt to Equity ratio of 0.0% means that company has $0.00 debt for each $1 in shareholders equity.

Let's take a look of the Debt to Equity Ratio trends of Endonovo Therapeutics Inc:

  • The MRQ is 0.000. The data is not here.
Trends
Current periodCompared to+/- 
MRQ-TTM-0.000
TTM-YOY-0.000
TTM-5Y-0.000
5Y-10Y-0.000
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ-0.366-0.366
TTM-0.415-0.415
YOY-0.369-0.369
5Y-0.441-0.441
10Y-0.483-0.483
3rd party ad coffee SUPPORTERis ad-free.

2. Market Valuation of Endonovo Therapeutics Inc

2.1. Earnings Per Share
2.1. Price to Earnings Ratio

Measures how much money you pay for each share for every $1 in earnings Endonovo generates.

  • Above 15 is considered overpriced but always compare Endonovo to the Biotechnology industry mean.
  • A PE ratio of -0.68 means the investor is paying $-0.68 for every $1 in earnings.

Let's take a look of the Price to Earnings Ratio trends of Endonovo Therapeutics Inc:

  • The EOD is -0.264. Based on the earnings, the company is expensive. -2
  • The MRQ is -0.683. Based on the earnings, the company is expensive. -2
  • The TTM is -0.055. Based on the earnings, the company is expensive. -2
Trends
Current periodCompared to+/- 
EOD-0.264MRQ-0.683+0.419
MRQ-0.683TTM-0.055-0.628
TTM-0.055YOY-0.411+0.356
TTM-0.0555Y-2.443+2.388
5Y-2.44310Y-34.060+31.617
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
EOD-0.264-2.571+2.307
MRQ-0.683-3.020+2.337
TTM-0.055-2.891+2.836
YOY-0.411-3.549+3.138
5Y-2.443-6.222+3.779
10Y-34.060-6.317-27.743
2.2. Price To Free Cash Flow Ratio

Let's take a look of the Price To Free Cash Flow Ratio trends of Endonovo Therapeutics Inc:

  • The EOD is -85.090. Based on how much money comes from the company's main activities, the company is expensive. -2
  • The MRQ is -219.816. Based on how much money comes from the company's main activities, the company is expensive. -2
  • The TTM is -66.184. Based on how much money comes from the company's main activities, the company is expensive. -2
Trends
Current periodCompared to+/- 
EOD-85.090MRQ-219.816+134.726
MRQ-219.816TTM-66.184-153.633
TTM-66.184YOY-5.597-60.587
TTM-66.1845Y-54.389-11.794
5Y-54.38910Y-117.423+63.033
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
EOD-85.090-3.225-81.865
MRQ-219.816-3.748-216.068
TTM-66.184-3.717-62.467
YOY-5.597-5.046-0.551
5Y-54.389-7.998-46.391
10Y-117.423-8.522-108.901
3rd party ad coffee SUPPORTERis ad-free.
2. Book Value per Share
2.3. Price to Book Ratio

Measures if the stock price of Endonovo is to cheap or to expensive compared to its book value.

  • At or below 1 is considered healthy (always compare to Biotechnology industry mean).
  • A PB ratio of -0.08 means the investor is paying $-0.08 for each $1 in book value.

Let's take a look of the Price to Book Ratio trends of Endonovo Therapeutics Inc:

  • The EOD is -0.030. Based on the equity, the company is expensive. -2
  • The MRQ is -0.078. Based on the equity, the company is expensive. -2
  • The TTM is -0.320. Based on the equity, the company is expensive. -2
Trends
Current periodCompared to+/- 
EOD-0.030MRQ-0.078+0.048
MRQ-0.078TTM-0.320+0.241
TTM-0.320YOY-0.168-0.152
TTM-0.3205Y-2.318+1.998
5Y-2.31810Y-19.051+16.733
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
EOD-0.0301.936-1.966
MRQ-0.0782.247-2.325
TTM-0.3202.301-2.621
YOY-0.1682.387-2.555
5Y-2.3183.666-5.984
10Y-19.0514.139-23.190
2. Total Gains per Share
3rd party ad coffee SUPPORTERis ad-free.

3. Summary

3.1. Key Performance Indicators

The key performance indicators of Endonovo Therapeutics Inc compared to the Most Recent Quarter (MRQ).

 End of day+/-Most Recent QuarterTrailing 12 Months+/-Year-Over-Year+/-5 Year+/-10 Year+/-
Book Value Change Per Share--0.0290.013+124%-0.012+140%0.000+101%-0.001+102%
Book Value Per Share---0.040-0.048+20%-0.074+86%-0.052+31%-0.038-5%
Current Ratio--0.0010.002-54%0.001+19%0.003-79%0.010-93%
Debt To Asset Ratio--53.07035.945+48%19.939+166%15.423+244%32.489+63%
Debt To Equity Ratio----0%-0%-0%-0%
Dividend Per Share----0%-0%-0%-0%
Eps---0.001-0.002+41%-0.019+1555%-0.007+522%-0.006+414%
Free Cash Flow Per Share--0.0000.000-101%-0.001+15759%-0.001+17808%-0.001+31253%
Free Cash Flow To Equity Per Share--0.0000.000+615%0.000+2174%0.000+58%0.001-100%
Gross Profit Margin--1.0001.0000%1.0000%1.0000%1.0000%
Intrinsic Value_10Y_max--0.019--------
Intrinsic Value_10Y_min---0.031--------
Intrinsic Value_1Y_max---0.001--------
Intrinsic Value_1Y_min---0.004--------
Intrinsic Value_3Y_max---0.001--------
Intrinsic Value_3Y_min---0.012--------
Intrinsic Value_5Y_max--0.002--------
Intrinsic Value_5Y_min---0.018--------
Market Cap419272.781-362%1938777.8327241662.944-73%4446038.446-56%44678850.229-96%114465010.361-98%
Net Profit Margin---84.631-202.768+140%-1315.096+1454%410.652-121%287.226-129%
Operating Margin---47.726-130.117+173%-705.147+1377%-303.115+535%-135.791+185%
Operating Ratio--48.725130.696-63%706.157-93%303.536-84%98.779-51%
Pb Ratio-0.030+61%-0.078-0.320+309%-0.168+114%-2.318+2865%-19.051+24270%
Pe Ratio-0.264+61%-0.683-0.055-92%-0.411-40%-2.443+258%-34.060+4885%
Price Per Share0.001-158%0.0030.010-68%0.013-76%0.126-98%0.327-99%
Price To Free Cash Flow Ratio-85.090+61%-219.816-66.184-70%-5.597-97%-54.389-75%-117.423-47%
Price To Total Gains Ratio0.041-158%0.106-0.653+718%-2.410+2381%-16.157+15392%-771.935+730693%
Quick Ratio--0.0000.000-98%0.000-97%0.002-100%0.005-100%
Return On Assets---1.489-0.725-51%-5.140+245%-1.532+3%-5.155+246%
Return On Equity----0%-0%-0%-0%
Total Gains Per Share--0.0290.013+124%-0.012+140%0.000+101%-0.001+102%
Usd Book Value---24800747.000-23517252.250-5%-25781662.750+4%-19572981.600-21%-13912606.200-44%
Usd Book Value Change Per Share--0.0290.013+124%-0.012+140%0.000+101%-0.001+102%
Usd Book Value Per Share---0.040-0.048+20%-0.074+86%-0.052+31%-0.038-5%
Usd Dividend Per Share----0%-0%-0%-0%
Usd Eps---0.001-0.002+41%-0.019+1555%-0.007+522%-0.006+414%
Usd Free Cash Flow---2205.00073205.250-103%-195356.250+8760%-226794.400+10185%-389323.000+17556%
Usd Free Cash Flow Per Share--0.0000.000-101%-0.001+15759%-0.001+17808%-0.001+31253%
Usd Free Cash Flow To Equity Per Share--0.0000.000+615%0.000+2174%0.000+58%0.001-100%
Usd Market Cap419272.781-362%1938777.8327241662.944-73%4446038.446-56%44678850.229-96%114465010.361-98%
Usd Price Per Share0.001-158%0.0030.010-68%0.013-76%0.126-98%0.327-99%
Usd Profit---709376.000-253821.000-64%-6766578.500+854%-2672320.450+277%-1809573.225+155%
Usd Revenue--8382.00015271.000-45%63634.000-87%43779.650-81%51556.975-84%
Usd Total Gains Per Share--0.0290.013+124%-0.012+140%0.000+101%-0.001+102%
 EOD+1 -7MRQTTM+17 -14YOY+24 -75Y+20 -1110Y+16 -15

3.2. Fundamental Score

Let's check the fundamental score of Endonovo Therapeutics Inc based on Penke's default stock scanner.

Penke's Stock Scanner

  
  
IndicatorConditionValue
Price to Earnings Ratio (EOD)Between0-15-0.264
Price to Book Ratio (EOD)Between0-1-0.030
Net Profit Margin (MRQ)Greater than0-84.631
Operating Margin (MRQ)Greater than0-47.726
Quick Ratio (MRQ)Greater than10.000
Current Ratio (MRQ)Greater than10.001
Debt to Asset Ratio (MRQ)Less than153.070
Debt to Equity Ratio (MRQ)Less than10.000
Return on Equity (MRQ)Greater than0.150.000
Return on Assets (MRQ)Greater than0.05-1.489
Total1/10 (10.0%)

3.3. Technical Score

Let's check the technical score of Endonovo Therapeutics Inc based on Penke's default Symbol scanner.

Penke's Symbol Scanner

  
  
IndicatorConditionValue
RsiGreater than5052.296
Ma 20Greater thanMa 500.001
Ma 50Greater thanMa 1000.001
Ma 100Greater thanMa 2000.002
OpenGreater thanClose0.001
Total1/5 (20.0%)



Latest Balance Sheet

Balance Sheet of 2024-03-31. Currency in USD. All numbers in thousands.

Summary
Total Assets476
Total Liabilities25,277
Total Stockholder Equity-24,801
 As reported
Total Liabilities 25,277
Total Stockholder Equity+ -24,801
Total Assets = 476

Assets

Total Assets476
Total Current Assets18
Long-term Assets458
Total Current Assets
Cash And Cash Equivalents 0
Other Current Assets 18
Total Current Assets  (as reported)18
Total Current Assets  (calculated)18
+/-0
Long-term Assets
Long-term Assets Other 457
Long-term Assets  (as reported)458
Long-term Assets  (calculated)457
+/- 2

Liabilities & Shareholders' Equity

Total Current Liabilities25,197
Long-term Liabilities80
Total Stockholder Equity-24,801
Total Current Liabilities
Short-term Debt 7,058
Accounts payable 1,097
Other Current Liabilities 17,042
Total Current Liabilities  (as reported)25,197
Total Current Liabilities  (calculated)25,197
+/-0
Long-term Liabilities
Long-term Liabilities  (as reported)80
Long-term Liabilities  (calculated)0
+/- 80
Total Stockholder Equity
Common Stock34
Retained Earnings -68,943
Accumulated Other Comprehensive Income -34
Other Stockholders Equity 44,143
Total Stockholder Equity (as reported)-24,801
Total Stockholder Equity (calculated)-24,801
+/- 0
Other
Cash and Short Term Investments 0
Common Stock Shares Outstanding 625,412
Liabilities and Stockholders Equity 476
Net Debt 7,058
Net Working Capital -25,179
Short Long Term Debt Total 7,058



Balance Sheet

Currency in USD. All numbers in thousands.

 Trend2024-03-312023-12-312023-09-302023-06-302023-03-312022-12-312022-09-302022-06-302022-03-312021-12-312021-09-302021-06-302021-03-312020-12-312020-09-302020-06-302020-03-312019-12-312019-09-302019-06-302019-03-312018-12-312018-09-302018-06-302018-03-312017-12-312017-09-302017-06-302017-03-312016-12-312016-09-302016-06-302016-03-312015-12-312015-09-302015-06-302015-03-312014-12-312014-09-302014-06-302014-03-312013-12-312013-09-302013-06-302013-03-312012-12-312012-09-302012-06-302012-03-312011-12-312011-09-302010-12-31
> Total Assets 
170
100
990
990
988
969
78
78
74
64
74
74
196
99
46
46
54
62
76
76
102
264
319
319
203
160
4,612
4,612
4,284
4,711
4,242
4,242
4,123
3,414
3,275
3,275
2,896
2,732
2,607
2,607
2,274
2,137
2,007
2,007
1,595
1,451
1,281
1,281
1,015
816
640
476
4766408161,0151,2811,2811,4511,5952,0072,0072,1372,2742,6072,6072,7322,8963,2753,2753,4144,1234,2424,2424,7114,2844,6124,61216020331931926410276766254464699196747464747878969988990990100170
   > Total Current Assets 
160
100
10
10
26
19
1
1
2
1
3
3
152
58
3
3
18
30
44
44
79
245
303
303
195
155
111
111
99
689
382
382
586
39
63
63
10
9
46
46
39
63
95
95
6
24
16
16
73
36
20
18
182036731616246959563394646910636339586382382689991111111551953033032457944443018335815233121119261010100160
       Cash And Cash Equivalents 
30
100
10
10
11
3
1
1
2
1
3
3
145
51
1
1
18
27
41
41
79
95
56
56
24
64
90
90
68
665
379
379
548
5
19
19
5
3
13
13
9
6
86
86
0
23
0
0
33
0
2
0
020330023086866913133519195548379379665689090642456569579414127181151145331211311101010030
       Net Receivables 
130
0
0
1
1
2
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
7
10
3
3
3
8
11
23
23
1
1
1
1
9
7
1
1
1
1
0
3
0
0
0
0
0000301111791111232311833310700000000000000000000021100130
       Other Current Assets 
0
0
0
0
14
14
0
0
0
0
0
0
7
7
2
2
0
3
3
3
0
150
247
247
171
91
21
21
21
21
0
0
0
0
0
21
3
3
0
32
21
50
0
8
5
0
16
16
40
36
18
18
18183640161605805021320332100000212121219117124724715003330227700000014140000
   > Long-term Assets 
10
0
980
980
962
949
77
77
72
63
70
70
44
41
43
43
35
32
32
32
24
20
0
16
8
5
0
4,501
4,185
4,023
0
3,860
3,537
3,375
3,212
3,212
2,886
2,723
2,561
2,561
2,236
2,074
1,912
1,912
1,589
1,427
1,265
1,265
942
780
620
458
4586207809421,2651,2651,4271,5891,9121,9122,0742,2362,5612,5612,7232,8863,2123,2123,3753,5373,86004,0234,1854,50105816020243232323543434144707063727777949962980980010
       Property Plant Equipment 
0
0
0
2
2
1
65
65
60
51
58
58
44
41
43
43
35
32
32
32
24
20
16
16
8
5
1
1
9
8
7
7
7
7
6
6
3
2
2
2
0
0
0
0
0
0
0
0
0
0
0
0
0000000000002223667777891158161620243232323543434144585851606565122000
       Intangible Assets 
0
0
980
980
960
948
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
4,500
4,500
4,177
4,015
3,853
3,853
3,530
3,368
3,206
3,206
2,883
2,721
2,559
2,559
2,236
2,074
1,912
1,912
1,589
1,427
1,265
1,265
942
780
619
0
06197809421,2651,2651,4271,5891,9121,9122,0742,2362,5592,5592,7212,8833,2063,2063,3683,5303,8533,8534,0154,1774,5004,5000000000000000000000094896098098000
       Long-term Assets Other 
10
0
0
-2
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
3,697
3,537
3,375
3,212
0
0
0
0
0
0
0
0
0
-2
-2
0
-2
-2
-2
0
457
4570-2-2-20-2-20000000003,2123,3753,5373,697000000000000000000000000000-20010
> Total Liabilities 
0
0
1,420
1,420
2,104
2,395
1,959
1,959
3,090
3,527
4,206
4,206
5,151
4,583
4,739
4,739
5,451
5,991
7,665
7,665
7,353
8,783
8,880
8,881
9,357
13,344
13,564
14,163
13,400
18,793
15,634
15,634
20,369
19,980
23,778
23,778
15,078
15,494
16,981
16,981
19,259
20,355
17,782
17,782
20,755
21,057
33,462
33,462
23,217
23,776
24,746
25,277
25,27724,74623,77623,21733,46233,46221,05720,75517,78217,78220,35519,25916,98116,98115,49415,07823,77823,77819,98020,36915,63415,63418,79313,40014,16313,56413,3449,3578,8818,8808,7837,3537,6657,6655,9915,4514,7394,7394,5835,1514,2064,2063,5273,0901,9591,9592,3952,1041,4201,42000
   > Total Current Liabilities 
0
0
670
670
1,199
1,645
1,753
1,753
2,880
3,329
4,008
4,008
4,961
4,396
4,555
4,555
5,274
5,813
7,483
7,483
6,962
8,289
8,721
8,721
9,202
13,189
13,409
13,409
12,323
17,474
15,479
15,479
20,214
19,825
23,623
23,623
14,923
15,339
16,826
16,826
19,179
20,275
17,702
17,702
20,675
20,977
33,382
33,382
23,137
23,696
24,666
25,197
25,19724,66623,69623,13733,38233,38220,97720,67517,70217,70220,27519,17916,82616,82615,33914,92323,62323,62319,82520,21415,47915,47917,47412,32313,40913,40913,1899,2028,7218,7218,2896,9627,4837,4835,8135,2744,5554,5554,3964,9614,0084,0083,3292,8801,7531,7531,6451,19967067000
       Short-term Debt 
0
0
180
180
415
570
236
236
436
495
715
715
1,350
1,208
1,388
1,388
1,298
1,499
1,519
1,519
1,408
1,559
3,824
2,061
2,380
2,727
4,465
4,735
6,133
7,237
0
6,324
6,782
7,133
0
6,862
6,206
6,101
0
6,634
6,659
6,772
0
7,181
7,357
7,240
0
7,153
7,027
7,057
7,073
7,058
7,0587,0737,0577,0277,15307,2407,3577,18106,7726,6596,63406,1016,2066,86207,1336,7826,32407,2376,1334,7354,4652,7272,3802,0613,8241,5591,4081,5191,5191,4991,2981,3881,3881,2081,35071571549543623623657041518018000
       Short Long Term Debt 
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
3,824
8,413
2,387
2,557
4,465
5,192
5,863
6,967
7,594
6,276
6,782
7,133
6,862
6,180
6,206
6,101
6,634
6,736
6,659
6,772
7,181
7,293
7,357
7,240
7,153
6,900
7,027
7,057
7,073
0
07,0737,0577,0276,9007,1537,2407,3577,2937,1816,7726,6596,7366,6346,1016,2066,1806,8627,1336,7826,2767,5946,9675,8635,1924,4652,5572,3878,4133,8240000000000000000000000
       Accounts payable 
0
0
0
1
0
0
0
1,983
2,444
2,834
3,294
3,750
3,612
3,188
3,167
3,412
3,758
3,809
3,990
4,223
4,379
4,552
4,727
4,686
4,674
3,238
2,714
2,992
3,070
3,180
157
157
281
346
599
599
609
762
701
701
711
753
658
658
786
866
882
884
1,449
1,460
1,080
1,097
1,0971,0801,4601,4498848828667866586587537117017017626095995993462811571573,1803,0702,9922,7143,2384,6744,6864,7274,5524,3794,2233,9903,8093,7583,4123,1673,1883,6123,7503,2942,8342,4441,9830001000
       Other Current Liabilities 
0
0
490
490
784
1,075
1,517
1,517
2,445
2,834
3,294
3,294
3,612
3,188
3,167
3,167
3,976
4,314
5,964
5,964
5,554
6,730
1,934
6,661
6,823
10,462
5,960
8,674
6,190
10,237
4,426
6,752
10,807
8,830
10,600
12,413
3,667
3,457
4,203
4,203
5,904
6,446
3,442
3,442
12,532
12,872
17,362
25,344
5,903
5,903
16,514
17,042
17,04216,5145,9035,90325,34417,36212,87212,5323,4423,4426,4465,9044,2034,2033,4573,66712,41310,6008,83010,8076,7524,42610,2376,1908,6745,96010,4626,8236,6611,9346,7305,5545,9645,9644,3143,9763,1673,1673,1883,6123,2943,2942,8342,4451,5171,5171,07578449049000
   > Long-term Liabilities 
0
0
750
750
905
750
207
207
209
198
197
197
190
187
184
184
178
178
183
183
391
495
0
159
155
155
0
753
1,077
1,320
0
155
155
155
155
155
155
155
155
155
80
80
80
80
80
80
80
80
80
80
80
80
80808080808080808080808015515515515515515515515515501,3201,0777530155155159049539118318317817818418418719019719719820920720775090575075000
       Other Liabilities 
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
155
155
155
155
155
155
155
155
155
155
155
155
155
155
155
155
155
80
80
80
80
80
80
80
0
0
0
0
0
000008080808080808015515515515515515515515515515515515515515515515515500000000000000000000000
> Total Stockholder Equity
170
100
-430
-430
-1,116
-1,426
-1,881
-1,881
-3,016
-3,463
-4,132
-4,132
-4,955
-4,484
-4,693
-4,693
-5,398
-5,929
-7,589
-7,589
-7,250
-8,519
-8,562
-8,562
-9,154
-13,184
-9,550
-9,550
-9,116
-14,082
-11,392
-11,392
-16,247
-16,566
-20,504
-20,504
-12,183
-12,762
-14,374
-14,374
-16,984
-18,218
-15,774
-15,774
-19,160
-19,606
-32,180
-32,180
-22,202
-22,960
-24,106
-24,801
-24,801-24,106-22,960-22,202-32,180-32,180-19,606-19,160-15,774-15,774-18,218-16,984-14,374-14,374-12,762-12,183-20,504-20,504-16,566-16,247-11,392-11,392-14,082-9,116-9,550-9,550-13,184-9,154-8,562-8,562-8,519-7,250-7,589-7,589-5,929-5,398-4,693-4,693-4,484-4,955-4,132-4,132-3,463-3,016-1,881-1,881-1,426-1,116-430-430100170
   Common Stock
0
0
0
5
5
5
5
5
7
8
8
8
5
8
8
8
10
10
10
10
12
12
13
13
24
28
32
32
36
38
43
43
73
83
0
0
1
2
2
2
6
7
7
7
15
16
21
21
28
28
33
34
343328282121161577762221008373434338363232282413131212101010108885888755555000
   Retained Earnings -68,943-68,234-66,631-65,864-75,119-75,119-61,986-61,383-56,443-56,443-58,840-57,316-53,339-53,339-51,308-50,239-52,935-52,935-47,270-45,864-35,620-35,620-37,002-31,054-29,184-29,184-30,953-24,281-18,374-18,374-17,634-15,416-11,372-11,372-8,532-7,331-6,293-6,293-6,070-6,165-5,333-5,333-4,659-4,207-2,441-2,441-1,851-1,458-440-440-560-490
   Capital Surplus 0000000000000000000000000000000000000000000000000000
   Treasury Stock0000000000000000000000000000000000000000000000000000
   Other Stockholders Equity 
660
660
10
10
337
420
554
554
1,184
1,188
1,193
1,193
1,205
1,579
1,592
1,592
1,962
2,635
3,819
3,819
8,208
9,162
-2
9,861
15,173
17,815
-2
19,680
21,981
22,962
-2
24,266
29,626
30,704
-2
32,515
38,142
38,631
-2
38,962
40,326
40,614
-2
40,662
42,209
42,366
-2
42,919
43,636
43,643
44,128
44,143
44,14344,12843,64343,63642,919-242,36642,20940,662-240,61440,32638,962-238,63138,14232,515-230,70429,62624,266-222,96221,98119,680-217,81515,1739,861-29,1628,2083,8193,8192,6351,9621,5921,5921,5791,2051,1931,1931,1881,1845545544203371010660660



Balance Sheet

Currency in USD. All numbers in thousands.




Cash Flow

Currency in USD. All numbers in thousands.




Income Statement

Currency in USD. All numbers in thousands.


Latest Income Statement (annual, 2023-12-31)

Gross Profit (+$)
totalRevenue140
Cost of Revenue-655
Gross Profit-515-515
 
Operating Income (+$)
Gross Profit-515
Operating Expense-2,405
Operating Income-2,919-2,919
 
Operating Expense (+$)
Research Development0
Selling General Administrative0
Selling And Marketing Expenses0
Operating Expense2,4050
 
Net Interest Income (+$)
Interest Income0
Interest Expense-1,282
Other Finance Cost-65
Net Interest Income-1,217
 
Pretax Income (+$)
Operating Income-2,919
Net Interest Income-1,217
Other Non-Operating Income Expenses0
Income Before Tax (EBT)6,925-12,763
EBIT - interestExpense = -4,202
6,925
8,207
Interest Expense1,282
Earnings Before Interest and Taxes (EBIT)-2,9198,207
Earnings Before Interest and Taxes (EBITDA)-2,273
 
After tax Income (+$)
Income Before Tax6,925
Tax Provision-0
Net Income From Continuing Ops-4,4046,925
Net Income6,925
Net Income Applicable To Common Shares0
 
Non-recurring Events
Discontinued Operations0
Extraordinary Items0
Effect of Accounting Charges0
Other Items0
Non Recurring0
Other Operating Expenses3,060
Total Other Income/Expenses Net9,8441,217
 

Technical Analysis of Endonovo
The psychology behind the price

Technical indicators reflecting market sentiment and the collective psychology of you and other traders. Your emotions and other traders' emotions, such as fear and greed, play a significant role in driving price movements.

General trend

First of all, I'm going to put something in the back of your mind. One of the most stable factors that gives you more confidence as a trader: the general trend of Endonovo. The general trend of Endonovo is BEARISH with 71.4% confidence. It is very important for your mental being to use each indicator with this in mind. But beware, also the general trend flips once in a while! You can use moving averages to determine Endonovo's overall trend. For convenience I use the most commonly used moving averages: 20, 50, 100 & 200. Of course you can use other moving averages or other indicators to determine the trend.

Indicator phases

Some of the indicators I use have 3 zones: overbought, oversold and neutral. Transitions between these zones (market phases) provide valuable trading signals and insights. Expecially with the general trend mind, I use the highlighted phases:

Indicator zone transitionsBullish trend (-71.4%) Bearish trend (71.4%)
Overbought to neutralBullish pullback=Bearish reversal
Upper to lower neutralBullish correction=Bearish continuation
Nuetral to oversoldOversold=Oversold
Oversold to neutralBullish reversal=Bearish correction
Lower to upper neutralBullish continuation=Bearish pullback
Nuetral to overboughtOverbought=Overbought

1. Price Targets

1.1 Support & Resistance

Support and resistance are levels on a price chart that act as barriers or zones where the price of an asset tends to stop, reverse, or experience a significant amount of buying or selling pressure.

Support is a price level at which demand for an asset is strong enough to prevent the price from falling further.
Resistance is a price level at which selling pressure becomes significant enough to prevent the price of an asset from rising further.


Score

Let's take a look at the Support & Resistance of Endonovo Therapeutics Inc.

The long score for the Support & Resistance is 0/1.
The longshort score for the Support & Resistance is 0/(-1 +1).

  • Between support/resistance: The price is trading between support and resistance lines.

The bullish price targets are: 0.0015 < 0.0017 < 0.0018.

The bearish price targets are: 0.0009 > 0.0009 > 0.0008.

Tweet this
Endonovo Therapeutics Inc Daily Support & Resistance Chart

2. Trend Indicators

2.1 Moving Averages

Shows the moving average of the selected period.

  • Moving averages are lagging trend indicators.
  • There are many types of moving averages.
  • Moving averages are also used within other indicators.

Score

Let's take a look at the Moving Averages of Endonovo Therapeutics Inc. The current mas is .

The long score for the Moving Averages is 2/14.
The longshort score for the Moving Averages is -10/(-14 +14).

  • MA 20 trending down: The MA 20 is trending down. -1
  • Close > MA 20: The price is above the MA 20. +1
  • MA 20 < MA 50: The MA 20 is lower than the MA 50. -1
  • MA 20 < MA 100: The MA 20 is lower than the MA 100. -1
  • MA 20 < MA 200: The MA 20 is lower than the MA 200. -1
  • MA 50 trending down: The MA 50 is trending down. -1
  • Close > MA 50: The price is above the MA 50. +1
  • MA 50 < MA 100: The MA 50 is lower than the MA 100. -1
  • MA 50 < MA 200: The MA 50 is lower than the MA 200. -1
  • MA 100 trending down: The MA 100 is trending down. -1
  • Close < MA 100: The price is below the MA 100. -1
  • MA 100 < MA 200: The MA 100 is lower than the MA 200. -1
  • MA 200 trending down: The MA 200 is trending down. -1
  • Close < MA 200: The price is below the MA 200. -1

Directionalities and relatives.

Moving AverageAmount of candlesTrendPrice +/-vs. MA 50vs. MA 100vs. MA 200
MA 2020
MA 5050-
MA 100100--
MA 200200---

Explanation: https://www.youtube.com/watch?v=xwW8h0lrQ-I

Endonovo Therapeutics Inc Daily Moving Averages Chart
2.2 Moving Average Convergence/Divergence (MACD)

Shows the momentum of the selected period based on two moving averages.

  • MACD is a lagging momentum indicator.
  • Uses two moving averages.
  • Can show buy or sell signals based on momentum.
  • Can show overbought. and oversold. levels.

Score

Let's take a look at the Moving Average Convergence/Divergence (MACD) of Endonovo Therapeutics Inc. The current macd is 0.00000.

The long score for the Moving Average Convergence/Divergence (MACD) is 4/4.
The longshort score for the Moving Average Convergence/Divergence (MACD) is 4/(-4 +4).

  • MACD line > signal line: The MACD line is above the signal line, which indicates a bullish signal in the market. This means that the positive momentum is currently stronger than the average momentum, suggesting that buyers are more active than sellers, and there's a higher probability of the Endonovo price going up in the near term. +2
  • MACD > 0: The MACD is above the zero line (centerline), it indicates a bullish signal for Endonovo. This means that the short-term moving average is higher than the long-term moving average, signaling positive momentum and suggesting a higher likelihood of the Endonovo price continuing to rise in the near future. It indicates that buyers are gaining control, and there is optimism in the market, leading to potential price increases. +1
  • Trending up: The MACD line is trending up. This indicates that the short-term moving average is rising faster than the long-term moving average, suggesting positive momentum in the market. This signals that buyers are becoming more active and confident, leading to potential price increases as traders anticipate further gains and are willing to buy at higher prices. +1
Endonovo Therapeutics Inc Daily Moving Average Convergence/Divergence (MACD) ChartEndonovo Therapeutics Inc Daily Moving Average Convergence/Divergence (MACD) Chart
2.3 Directional Movement Index (DMI)

The DMI is a collection of 3 indicators: +DI (Plus Direction Indicator), -DI (Minus Direction Indicator) and ADX (Average Directional Index). The ADX helps you determine the strength of a trend.


Score

Let's take a look at the Directional Movement Index (DMI) of Endonovo Therapeutics Inc. The current adx is 16.33.

The long score for the Directional Movement Index (DMI) is 1/7.
The longshort score for the Directional Movement Index (DMI) is 1/(-7 +7).

  • PLUS_ID > MINUS_DI: The +DI line is above the -DI line. This indicates a bullish signal in the market, as the positive directional movement is currently stronger than the negative directional movement, showing that buyers have the upper hand. Market psychology suggests that traders are optimistic, expecting further price increases, and are more willing to buy Endonovo shares, leading to potential upward momentum in its price. +1
  • PLUS_ID > MINUS_DI && ADX < 25 && ADX trending down: The ADX is below 25 and indicates a weak or no trend. Also, the ADX is declining so there is no trend indication.
Endonovo Therapeutics Inc Daily Directional Movement Index (DMI) Chart
2.4 Parabolic SAR

Shows the current trend and potential entry and exit signals.

  • Parabolic SAR (stop and reverse) is a lagging trend indicator.
  • Shows the current trend.
  • Shows potential entry signals.
  • Shows  potential exit signals.
  • Can be used to place trailing stoplosses..

Score

Let's take a look at the Parabolic SAR of Endonovo Therapeutics Inc. The current sar is 0.00146471.

The long score for the Parabolic SAR is 0/1.
The longshort score for the Parabolic SAR is -1/(-1 +1).

  • Close < SAR: The price is below the SAR. It's generally considered a bearish signal. -1
Endonovo Therapeutics Inc Daily Parabolic SAR Chart
3rd party ad coffee SUPPORTERis ad-free.

3. Momentum Indicators

3.1 Relative Strength Index (RSI)

Measures the speed and change of price movements.

  • Leading momentum indicator, meaning the signals are instant.
  • Ranges between 0 and 100.
  • Above 70 is considered overbought.
  • Below 30 is considered oversold.
  • Above or below 50 can also be used to determine price trend or support and resistance.
  • RSI divergence looks at a deviation between RSI and price movement. Penketrading automatically calculates RSI divergences.
  • Can be used in many different ways

Score

Let's take a look at the Relative Strength Index (RSI) of Endonovo Therapeutics Inc. The current rsi is 52.30. The current phase is Correction in bear market.

The long score for the Relative Strength Index (RSI) is 3/13.
The longshort score for the Relative Strength Index (RSI) is 3/(-13 +13).

  • Correction in bear market: Extended price decline in a downtrend, significant pullback. Consider reducing exposure, wait for signs of trend reversal.
Endonovo Therapeutics Inc Daily Relative Strength Index (RSI) ChartEndonovo Therapeutics Inc Daily Relative Strength Index (RSI) Chart
3.2 Stochastic Oscillator

Compares a certain price to multiple prices ranging over time.

  • Leading momentum indicator, meaning the signals are instant.
  • Used to determine overbought and oversold areas much like the RSI.
  • Ranges between 0 and 100.
  • Above 80 is considered overbought.
  • Below 20 is considered oversold.
  • Consists of two lines named K and D.
  • K compares the highest high and lowest low on the selected price range.
  • The D line is a moving average of the K line.
  • Can be used to spot divergences

Score

Let's take a look at the Stochastic Oscillator of Endonovo Therapeutics Inc. The current phase is Correction in bear market.

The long score for the Stochastic Oscillator is 1/6.
The longshort score for the Stochastic Oscillator is -2/(-6 +6).

  • STOCH > 50: The STOCH %K is above 50. There are more buyers than sellers. +1
  • STOCH %K line < STOCH %D line: The STOCH %K line is below the STOCH %D line, which indicates a bearish signal in the market. This means that the negative momentum is currently stronger than the average momentum, suggesting that sellers are more active than buyers, and there's a higher probability of the Endonovo price going down in the near term. -2
  • Trending down: The STOCH %K is trending down. -1
Endonovo Therapeutics Inc Daily Stochastic Oscillator ChartEndonovo Therapeutics Inc Daily Stochastic Oscillator Chart
3.3 Commodity Channel Index (CCI)

Measures the difference between the current price and the historical average price.

  • Lagging or leading Momentum indicator
  • When the CCI is above zero, the price is above the historical average
  • When the CCI is below zero, the price is below the historical average
  • Used for spotting trends
    • If the CCI moves from negative or near zero to positive 100 that might indicate an uptrend
    • If the CCI moves from positive or near zero to negative -100 that might indicate a downtrend

Score

Let's take a look at the Commodity Channel Index (CCI) of Endonovo Therapeutics Inc. The current cci is 54.15.

Endonovo Therapeutics Inc Daily Commodity Channel Index (CCI) ChartEndonovo Therapeutics Inc Daily Commodity Channel Index (CCI) Chart
3.4 Chande Momentum Oscillator (CMO)

Measures the difference between the sum of recent gains and the sum of recent losses. Then divides the result by the sum of all price movements in that period.

  • Lagging momentum indicator
  • Ranges between +100 and -100
  • Considered overbought above +50
  • Considered oversold below -50
  • It's possible to add a moving average that acts as a signal line

Score

Let's take a look at the Chande Momentum Oscillator (CMO) of Endonovo Therapeutics Inc. The current cmo is 11.80.

The long score for the Chande Momentum Oscillator (CMO) is 1/1.
The longshort score for the Chande Momentum Oscillator (CMO) is 1/(-1 +1).

  • CMO > 0: The CMO is above 0, the momentum of the price is positive, indicating a potential uptrend in the price. +1
Endonovo Therapeutics Inc Daily Chande Momentum Oscillator (CMO) ChartEndonovo Therapeutics Inc Daily Chande Momentum Oscillator (CMO) Chart
3.5 Williams %R

 Shows the current price relative to the highest high over the last 14 days.
 

  • Lagging momentum indicator
  • Ranging between 0 and -100
  • Above -20 is considered overbought
  • Below -80 is considered oversold
  • Is prone to give false signals

Score

Let's take a look at the Williams %R of Endonovo Therapeutics Inc. The current willr is -40.

The long score for the Williams %R is 0/1.
The longshort score for the Williams %R is 0/(-1 +1).

  • WILLR between -80 and -20: The Williams %R is between -80 and -20. This indicates that Endonovo is trading in a neutral price range, neither oversold nor overbought, suggesting a balanced market condition without any extreme price signals.
Endonovo Therapeutics Inc Daily Williams %R ChartEndonovo Therapeutics Inc Daily Williams %R Chart
3rd party ad coffee SUPPORTERis ad-free.

4. Volatility Indicators

4.1 Bollinger Bands

Shows if the price is to high or to low relative to an average.

  • Lagging volatility indicator
  • Uses 3 bands: one upper, one lower and one in the middle
  • Works best when the middle band reflects an intermediate trend (MA20).
  • When the price is moving closer to the upper band, the market might be overbought
  • When the price is moving closer to the lower band, the market might be oversold 

Score

Let's take a look at the Bollinger Bands of Endonovo Therapeutics Inc.

Endonovo Therapeutics Inc Daily Bollinger Bands Chart
4.2 Average True Range (ATR)
Measures market volatility
  • Leading volatility indicator
  • Can be used to determine stop-loss positions
  • Calculated by:
    • Current high minus the current low
    • Current high minus the previous close
    • Current low minus the previous close
  • The larger the range of the candles, the greater the ATR value

Score

Let's take a look at the Average True Range (ATR) of Endonovo Therapeutics Inc. The current atr is 0.00015562.

Endonovo Therapeutics Inc Daily Average True Range (ATR) ChartEndonovo Therapeutics Inc Daily Average True Range (ATR) Chart
3rd party ad coffee SUPPORTERis ad-free.

5. Volume Indicators

5.1 On-Balance Volume (OBV)

 Measures market volatility

  • Leading momentum indicator
  • Calculation:
    • If the closing price is above the previous closing price: OBV = previous OBV + current volume
    • If the closing price is below the previous closing price: OBV = previous OBV - current volume
    • If the closing price is the same as the previous closing price than the OBV is the same.
  • Can be used to confirm price trends
  • Can be used with divergences

Score

Let's take a look at the On-Balance Volume (OBV) of Endonovo Therapeutics Inc. The current obv is 36,779,390.

Endonovo Therapeutics Inc Daily On-Balance Volume (OBV) ChartEndonovo Therapeutics Inc Daily On-Balance Volume (OBV) Chart
5.2 Money Flow Index (MFI)

Measures the flow of money in and out of a security

  • Lagging momentum indicator
  • Looks like RSI but uses volume as an extra metric (RSI only considers price)
  • Above 80 is considered overbought
  • Below 20 is considered oversold
  • Can be used with divergences

Score

Let's take a look at the Money Flow Index (MFI) of Endonovo Therapeutics Inc. The current mfi is 73.89.

The long score for the Money Flow Index (MFI) is 1/2.
The longshort score for the Money Flow Index (MFI) is 1/(-2 +2).

  • MFI > 50: +1
Endonovo Therapeutics Inc Daily Money Flow Index (MFI) ChartEndonovo Therapeutics Inc Daily Money Flow Index (MFI) Chart
3rd party ad coffee SUPPORTERis ad-free.

6. Summary

6.1. Notifications

TypeNotificationDate
PenkeCurrently no notifications for Endonovo Therapeutics Inc.

6.2. Trading Signals

Below you will find trading signals as the indicator is commonly used. This doesn't mean you should use it that way. Learn from these, but don't use them blindly. I recommend using at least 4 indicators, 1 from each category: trend, momentum, volatility and volume.

DateIndicatorSignal
2024-03-05STOCH SHORT EXITThe %K line crosses above the %D line.
2024-03-06CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
2024-03-07WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
2024-03-11WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
2024-03-13STOCH LONG EXITThe %K line crosses below the %D line.
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
2024-03-14CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
BB LONG ENTRY SHORT CLOSEPrice closed below the lower band.
2024-03-15STOCH SHORT EXITThe %K line crosses above the %D line.
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2024-03-18SAR SHORT ENTRY LONG CLOSEThe price broke the SAR to the downside
STOCH LONG EXITThe %K line crosses below the %D line.
CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
BB LONG ENTRY SHORT CLOSEPrice closed below the lower band.
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
2024-03-19STOCH SHORT EXITThe %K line crosses above the %D line.
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2024-03-20CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
2024-03-21MACD SHORT ENTRY LONG CLOSEThe MACD line crosses below the signal line.
STOCH LONG EXITThe %K line crosses below the %D line.
CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2024-03-22MACD LONG ENTRY SHORT CLOSEThe MACD line crosses above the signal line.
STOCH SHORT EXITThe %K line crosses above the %D line.
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
MFI SHORT ENTRY LONG CLOSE20 crossover to downside
2024-03-25CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
MFI LONG ENTRY SHORT CLOSE20 crossover to upside
2024-03-26STOCH LONG EXITThe %K line crosses below the %D line.
CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
MFI SHORT ENTRY LONG CLOSE20 crossover to downside
2024-03-27MACD SHORT ENTRY LONG CLOSEThe MACD line crosses below the signal line.
2024-03-28MACD LONG ENTRY SHORT CLOSEThe MACD line crosses above the signal line.
DMI LONG ENTRY SHORT CLOSEThe +DI crossed the -DI to the upside. The trend is reversing to an up trend.
SAR LONG ENTRY SHORT CLOSEThe price broke the SAR to the upside.
STOCH SHORT EXITThe %K line crosses above the %D line.
MFI LONG ENTRY SHORT CLOSE80 crossover to upside
2024-04-01STOCH LONG EXITThe %K line crosses below the %D line.
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
MFI SHORT ENTRY LONG CLOSE80 crossover to downside
2024-04-02CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
2024-04-03STOCH SHORT EXITThe %K line crosses above the %D line.
2024-04-04SAR SHORT ENTRY LONG CLOSEThe price broke the SAR to the downside
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
2024-04-09STOCH LONG EXITThe %K line crosses below the %D line.
2024-04-10CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2024-04-12STOCH SHORT EXITThe %K line crosses above the %D line.
2024-04-15CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
2024-04-17STOCH LONG EXITThe %K line crosses below the %D line.
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
MFI LONG ENTRY SHORT CLOSE80 crossover to upside
2024-04-18STOCH SHORT EXITThe %K line crosses above the %D line.
2024-04-22DMI SHORT ENTRY LONG CLOSEThe +DI crossed the -DI to the downside. The trend is reversing to a down trend.
STOCH LONG EXITThe %K line crosses below the %D line.
2024-04-24DMI LONG ENTRY SHORT CLOSEThe +DI crossed the -DI to the upside. The trend is reversing to an up trend.
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2024-04-25CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
2024-04-26STOCH SHORT EXITThe %K line crosses above the %D line.
2024-04-29MACD SHORT ENTRY LONG CLOSEThe MACD line crosses below the signal line.
DMI SHORT ENTRY LONG CLOSEThe +DI crossed the -DI to the downside. The trend is reversing to a down trend.
STOCH LONG EXITThe %K line crosses below the %D line.
CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
2024-04-30MACD LONG ENTRY SHORT CLOSEThe MACD line crosses above the signal line.
STOCH SHORT EXITThe %K line crosses above the %D line.
2024-05-01CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
2024-05-02MACD SHORT ENTRY LONG CLOSEThe MACD line crosses below the signal line.
STOCH LONG EXITThe %K line crosses below the %D line.
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
BB LONG ENTRY SHORT CLOSEPrice closed below the lower band.
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
2024-05-03MACD LONG ENTRY SHORT CLOSEThe MACD line crosses above the signal line.
STOCH SHORT EXITThe %K line crosses above the %D line.
MFI SHORT ENTRY LONG CLOSE20 crossover to downside
2024-05-06CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
2024-05-07MFI LONG ENTRY SHORT CLOSE20 crossover to upside
2024-05-10MACD SHORT ENTRY LONG CLOSEThe MACD line crosses below the signal line.
STOCH LONG EXITThe %K line crosses below the %D line.
CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
BB LONG ENTRY SHORT CLOSEPrice closed below the lower band.
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
MFI SHORT ENTRY LONG CLOSE20 crossover to downside
2024-05-13STOCH SHORT EXITThe %K line crosses above the %D line.
2024-05-14STOCH LONG EXITThe %K line crosses below the %D line.
BB LONG ENTRY SHORT CLOSEPrice closed below the lower band.
2024-05-16STOCH SHORT EXITThe %K line crosses above the %D line.
2024-05-17STOCH LONG EXITThe %K line crosses below the %D line.
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
BB LONG ENTRY SHORT CLOSEPrice closed below the lower band.
2024-05-21STOCH SHORT EXITThe %K line crosses above the %D line.
2024-05-23STOCH LONG EXITThe %K line crosses below the %D line.
2024-05-29CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2024-05-30STOCH SHORT EXITThe %K line crosses above the %D line.
MFI LONG ENTRY SHORT CLOSE20 crossover to upside
2024-06-03STOCH LONG EXITThe %K line crosses below the %D line.
CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2024-06-04STOCH SHORT EXITThe %K line crosses above the %D line.
2024-06-05MACD LONG ENTRY SHORT CLOSEThe MACD line crosses above the signal line.
2024-06-07STOCH LONG EXITThe %K line crosses below the %D line.
2024-06-10CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2024-06-12CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
2024-06-13SAR LONG ENTRY SHORT CLOSEThe price broke the SAR to the upside.
STOCH SHORT EXITThe %K line crosses above the %D line.
2024-06-14STOCH LONG EXITThe %K line crosses below the %D line.
2024-06-17STOCH SHORT EXITThe %K line crosses above the %D line.
2024-06-18CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
2024-06-20DMI LONG ENTRY SHORT CLOSEThe +DI crossed the -DI to the upside. The trend is reversing to an up trend.
CCI LONG ENTRY SHORT CLOSE100 crossover to upside
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
BB SHORT ENTRY LONG CLOSEPrice closed above the lower band.
2024-06-24STOCH LONG EXITThe %K line crosses below the %D line.
2024-06-26DMI SHORT ENTRY LONG CLOSEThe +DI crossed the -DI to the downside. The trend is reversing to a down trend.
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
2024-07-01DMI LONG ENTRY SHORT CLOSEThe +DI crossed the -DI to the upside. The trend is reversing to an up trend.
2024-07-02DMI SHORT ENTRY LONG CLOSEThe +DI crossed the -DI to the downside. The trend is reversing to a down trend.
SAR SHORT ENTRY LONG CLOSEThe price broke the SAR to the downside
2024-07-05WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2024-07-08MACD SHORT ENTRY LONG CLOSEThe MACD line crosses below the signal line.
2024-07-11MFI SHORT ENTRY LONG CLOSE20 crossover to downside
2024-07-12MACD LONG ENTRY SHORT CLOSEThe MACD line crosses above the signal line.
DMI LONG ENTRY SHORT CLOSEThe +DI crossed the -DI to the upside. The trend is reversing to an up trend.
2024-07-16CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
2024-07-18MFI LONG ENTRY SHORT CLOSE20 crossover to upside
2024-07-23CCI LONG ENTRY SHORT CLOSE100 crossover to upside
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
MFI SHORT ENTRY LONG CLOSE20 crossover to downside
2024-07-25STOCH LONG EXITThe %K line crosses below the %D line.
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).

6.3. Candlestick Patterns

Endonovo Therapeutics Inc Daily Candlestick Chart
DateCandlestick Pattern

6.4. Technical Score

Let's check the technical score of Endonovo Therapeutics Inc based on Penke's default Symbol scanner.

Penke's Symbol Scanner

  
  
IndicatorConditionValue
RsiGreater than5052.296
Ma 20Greater thanMa 500.001
Ma 50Greater thanMa 1000.001
Ma 100Greater thanMa 2000.002
OpenGreater thanClose0.001
Total1/5 (20.0%)
Penke

Good job! You gained 25 XP and 0   0   10 . What's next:

  • Share my analysis of Endonovo with someone you think should read this too:
  • Are you bullish or bearish on Endonovo? Let me know what you think in the comments.
  • Do you want an email if I find something interesting about Endonovo? Add an email alert using the form below.
  • Join the community if you want to keep your earnings and track your progress: Join the community
  • Is this analysis useful to you? Support me via But Me a Coffee. I'll analyze the stock market faster for you!

Get notifications about Endonovo Therapeutics Inc

I send you an email if I find something interesting about Endonovo Therapeutics Inc.


Comments

How you think about this?

Leave a comment

Stay informed about Endonovo Therapeutics Inc.

Receive notifications about Endonovo Therapeutics Inc in your mailbox!

3rd party ad coffee SUPPORTERis ad-free.